Human papillomavirus vaccination in males: The state of the science

Current Infectious Disease Reports

Volumn 13, Issue 2, 2011, Pages 175-181

  Barroso II, Luis F ^a   Wilkin, Timothy ^b  

^a WAKE FOREST UNIVERSITY HEALTH SCIENCES   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Acquired immunodeficiency syndrome; AIDS; Anal cancer; Anal dysplasia; Anogenital warts; Cancer; Cervical cancer; Cervical dysplasia; Condyloma acuminata; HIV; HPV; Human immunodeficiency virus; Human papillomavirus; Oropharyngeal cancer; Oropharyngeal dysplasia; Penile cancer; Penile dysplasia; Quadrivalent vaccine; Sexually transmitted infections; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ANUS CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSPLASIA; HUMAN; IMMUNOGENICITY; INFECTION RISK; MOUTH CANCER; NONHUMAN; PAPILLOMAVIRUS INFECTION; PENIS CANCER; REVIEW; TREATMENT PLANNING; VACCINATION; VIRUS TRANSMISSION;

EID: 79955953501     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-010-0163-7     Document Type: Review

References (48)

1. Marur S, D'Souza G, Westra WH, Forastiere AA: HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 2010;11:781-9.
2. Johnson LG, Madeleine MM, Newcomer LM, et al.: Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-8.
3. von Krogh G, Lacey CJ, Gross G, et al.: European guideline for the management of anogenital warts. Int J STD AIDS 2001;12 Suppl 3:40-7.
4. Munoz N, Bosch FX, de Sanjose S, et al.: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27. (Pubitemid 36159887)
5. Nielson CM, Flores R, Harris RB, et al.: Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev 2007;16:1107-14. (Pubitemid 46984945)
6. Barzon L, Militello V, Pagni S, et al.: Distribution of human papillomavirus types in the anogenital tract of females and males. J Med Virol 2010;82:1424-30.
7. Giuliano AR, Lazcano-Ponce E, Villa LL, et al.: The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States. Cancer Epidemiol Biomarkers Prev 2008;17:2036-43.
8. Stebbing J, Portsmouth S, Fox P, et al.: Multiple human papillomavirus types appear to be a feature of anal not cervical intra-epithelial neoplasia. AIDS 2003;17:2401. (Pubitemid 38147030)
9. Frisch M, Biggar RJ, Goedert JJ: Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000;92:1500-10.
10. Palefsky JM, Holly EA, Ralston ML, Jay N: Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998;177:361-7. (Pubitemid 28063760)
11. Parkin DM, Bray F: Chapter 2: The burden of HPV-related cancers. Vaccine 2006;24 Suppl 3:S3/11-25.
12. Parkin DM: The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
13. Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9. (Pubitemid 29406813)
14. Chaturvedi AK, Engels EA, Anderson WF, Gillison ML: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 2008;26:612-9. (Pubitemid 351264356)
15. Johnson LG, Madeleine MM, Newcomer LM, et al.: Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004;101:281-8.
16. Hernandez BY, Barnholtz-Sloan J, German RR, et al.: Burden of invasive squamous cell carcinoma of the penis in the United States, 1998-2003. Cancer 2008;113:2883-91.
17. Heideman DA, Waterboer T, Pawlita M, et al.: Human papillomavirus-16 is the predominant type etiologically involved in penile squamous cell carcinoma. J Clin Oncol 2007;25:4550-6. (Pubitemid 350035311)
18. Maden C, Sherman KJ, Beckmann AM, et al.: History of circumcision, medical conditions, and sexual activity and risk of penile cancer. J Natl Cancer Inst 1993;85:19-24. (Pubitemid 23023218)
19. Rubin MA, Kleter B, Zhou M, et al.: Detection and typing of human papillomavirus DNA in penile carcinoma: evidence for multiple independent pathways of penile carcinogenesis. Am J Pathol 2001;159:1211-8. (Pubitemid 32947950)
20. Tsen HF, Morgenstern H, Mack T, Peters RK: Risk factors for penile cancer: results of a population-based case-control study in Los Angeles County (United States). Cancer Causes Control 2001;12:267-77. (Pubitemid 32515374)
21. Chiao EY, Krown SE, Stier EA, Schrag D: A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005;40:451-5. (Pubitemid 41669180)
22. Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al.: Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010, 24(4):535-43. This article supports the rising incidence of anal cancer and the idea that HAART paradoxically increases the incidence of this HIV-related condition through increased survival.
23. Piketty C, Selinger-Leneman H, Grabar S, et al.: Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 2008;22:1203-11.
24. Piketty C, Darragh TM, Da Costa M, et al.: High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med 2003;138:453-9.
25. Sunesen KG, Norgaard M, Thorlacius-Ussing O, Laurberg S: Immunosuppressive disorders and risk of anal squamous cell carcinoma: A nationwide cohort study in Denmark, 1978-2005. Int J Cancer 2009;
26. Palefsky JM, Holly EA, Ralston ML, et al.: Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:320-6.
27. Palefsky JM, Holly EA, Efirdc JT, et al.: Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS 2005;19:1407-14. (Pubitemid 41800677)
28. Marchesa P, Fazio VW, Oliart S, et al.: Perianal Bowen's disease: a clinicopathologic study of 47 patients. Dis Colon Rectum 1997;40:1286-93. (Pubitemid 27498363)
29. Marfing TE, Abel ME, Gallagher DM: Perianal Bowen's disease and associated malignancies. Results of a survey. Dis Colon Rectum 1987;30:782-5. (Pubitemid 17168047)
30. Berry M, Jay N, Cranston R, et al.: Progression of High-Grade Anal Intraepithelial Neoplasia to Invasive Anal Cancer among HIV+Men Who Have Sex with Men. Abstract Number 867, Conference on Retroviruses and Opportunistic Infections, Montreal Canada 2009
31. D'Souza G, Kreimer AR, Viscidi R, et al.: Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356:1944-56. (Pubitemid 46740304)
32. Ragin CC, Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007;121:1813-20. (Pubitemid 47417302)
33. D'Souza G, Fakhry C, Sugar EA, et al.: Six-month natural history of oral versus cervical human papillomavirus infection. Int J Cancer 2007;121:143-50. (Pubitemid 46753862)
34. Clarke P, Ebel C, Catotti DN, Stewart S: The psychosocial impact of human papillomavirus infection: implications for health care providers. Int J STD AIDS 1996;7:197-200. (Pubitemid 26191688)
35. Smith JS, Moses S, Hudgens MG, et al.: Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. J Infect Dis 2010;201:1677-85.
36. Larson DA, Derkay CS: Epidemiology of recurrent respiratory papillomatosis. APMIS 2010;118:450-4.
37. Giuliano A, Palefsky J: The efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress 2008; Abstract TC 2-11. These phase III trials provide the most direct data for HPV vaccination of young men.
38. Giuliano A, Palefsky J: Efficacy of the quadrivalent HPV (types 6/11/16/18) vaccine in reducing the incidence of HPV-related genital disease in young men. Proceedings from the European Research Organization on Genital Infection and Neoplasia Congress 2008; Abstract SS 19-7a. These phase III trials provide the most direct data for HPV vaccination of young men.
39. Giuliano A, Palefsky J: Quadrivalent HPV vaccine efficacy against an HPV infection in men. 26th International Papillomavirus Conference and Clinical and Public Health Workshops [abstract P-669]. July 5, 2010, Montreal, Canada. 28
40. Palefsky J: Efficacy of the quadrivalent HPV vaccine to prevent anal intraepithelial neoplasia among young men who have sex with men. 26th International Papillomavirus Conference & Clinical and Public Health Workshops [abstract 456]. July 5, 2010, Montreal, Canada. 29
41. Reisinger KS, Block SL, Lazcano-Ponce E, et al.: Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26:201-9.
42. Wilkin T, Lee JY, Lensing SY, et al.: Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202:1246-53. This article demonstrates that HPV vaccination results in noninferior titers in HIV-infected men. This finding is particularly important given the increased disease burden of HPV in this cohort.
43. Brown V, White KA: The HPV vaccination strategy: could male vaccination have a significant impact? Comput Math Methods Med 2010;1.
44. Elbasha EH, Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;
45. Watson JC, Hadler SC, Dykewicz CA, et al.: Measles, mumps, and rubella-vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998;47:1-57.
46. Kim JJ, Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884. A key article in the debate about cost effectiveness, it highlights the difficulty of computing cost effectiveness and the immense variation that can take place with variations in variables.
47. Annemans L, Remy V, Oyee J, Largeron N: Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. Pharmacoeconomics 2009;27:231-45.
48. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845-52. This article provides a clear illustration of the importance of subpopulations when assessing HPV vaccine cost effectiveness in males.